Abstract:Abstract Importance The SARS-CoV-2 alpha variant posed increased risk for COVID-19 complications in pregnant women. However, its impact on the maternal humoral response and placental IgG transport remains unclear. Objective To characterize the maternal humoral waning and neonate immunity acquired during the 3 rd COVID-19 wave in Israel, dominated by the Alpha variant, as compared to earlier Wildtype infections and humoral response to vaccination across gestation. Design Maternal and fetal blood serum were collected at delivery since April 2020 from parturients. Sera IgG and IgM titers were measured using the Milliplex MAP SARS-CoV-2 Antigen Panel supplemented with additional HA-coupled microspheres. Setting A nationwide multicenter cohort study on SARS-CoV-2 infections and vaccination during pregnancy. Participants Expectant women presenting for delivery were recruited at 8 medical centers across Israel and assigned to 3 primary groups: SARS-CoV-2 positive ( n = 157) and fully vaccinated during pregnancy ( n = 125), and unvaccinated noninfected controls matched to the infected group by BMI, maternal age, comorbidities and gestational age ( n = 212). Eligibility criteria included pregnant women without active COVID-19 disease, age ≥18 years and willingness to provide informed consent. Main Outcome(s) and Measure(s) Pregnant women’s humoral response is dependent on the SARS-CoV-2 strain. Results The humoral response to infection as detected at birth, showed a gradual and significant decline as the interval between infection/vaccination and delivery increased. Significantly faster decay of antibody titers was found for infections occurring during the 3 rd wave compared to earlier infections/vaccination. Cord blood IgG antigens levels correlated with maternal IgG. However, cord IgG-HA variance significantly differed in SARS-CoV2 infections as compared to the other groups. No sexual dimorphism in IgG transfer was observed. Lastly, high fetal IgM response to SARS-CoV-2 was detected in 17 neonates, all showing elevated IgM to N suggesting exposure to SARS-Cov-2 antigens. Conclusions and Relevance Infections occurring during the 3 rd wave induced a faster decline in humoral response when compared to Wildtype infections or mRNA BNT162b2 vaccination during pregnancy, consistent with a shift in disease etiology and severity induced by the Alpha variant. Vaccination policies in previously infected pregnant women should consider the timing of exposure along pregnancy as well as the risk of infection to specific variants of concern. Key Points Question What is the difference in the maternal-fetal humoral response between Alpha variant and SARS-CoV-2 Wildtype infections? Findings In this nationwide multicenter study including 494 pregnant women, the maternal humoral response to Alpha variant infection was weaker and shorter when compared to Wildtype infections. Placental transport compensated for the maternal waning of immunity. Fetal sex did not affect humoral response. Meaning Vaccination policies should be adjusted to account for the timing of infection and the SARS-CoV-2 variant.

COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood

High transferability of neutralizing antibodies against SARS-CoV-2 to umbilical cord blood in pregnant women with BNT162b2 XBB.1.5 vaccine - a retrospective cohort study

Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy

Impact of Antenatal SARS-CoV-2 Exposure on SARS-CoV-2 Neutralization Potency

COVID-19 vaccination before or during pregnancy results in high, sustained maternal neutralizing activity to SARS-CoV-2 wild-type and Delta/Omicron variants of concern, particularly following a booster dose or infection

Diverging maternal and infant cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy

Neutralizing and binding antibody responses to SARS-CoV-2 with hybrid immunity in pregnancy

Insights from Maternal Vaccination and COVID-19 Infection

Immune Response and Transplacental Antibody Transfer in Pregnant Women after COVID-19 Vaccination

Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study

Maternal antibody transfer rate of vaccination against SARS‐CoV‐2 before or during early pregnancy and its protective effectiveness on offspring

Maternal and neonatal outcomes of COVID-19 vaccination during pregnancy, a systematic review and meta-analysis

Waning of the Humoral Response to SARS-CoV-2 in Pregnancy is Variant-Dependent

Placental transfer dynamics and durability of maternal COVID-19 vaccine-induced antibodies in infants

Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants

Timing of maternal vaccination against COVID-19 for effective protection of neonates: cohort study

Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy

COVID-Vaccines in Pregnancy: Maternal and Neonatal Response over the First 9 Months after Delivery